Institut National De La Sante Et De La Recherche Medicale

Innavirvax

Ciba-geigy Corporation

Université Pierre Et Marie Curie (paris Vi)

Assistance Publique-hopitaux De Paris

Universitè De Genève

Inserm

Minka Therapeutics

Patrice Debre

Robin E Offord

Joël Crouzet

Vincent Vieillard

Oliver Hartley

Guy Gorochov

Mohammad D Mossalayi

Laurence Meyer

Karim Dorgham

Vincent Viellard

The present invention relates to an immunogenic composition comprising an antigenic peptide of formula (I) below: Nt-S-X1-X2-X3-K-X4-Ct (I) [SEQ ID No 1], wherein Nt consists of a peptide having from 0 to 50 amino acids in length, Ct consists of a peptide having from 0 to 50 amino acids in length, each of X1 to X4 consists of an amino acid residue, wherein: (i) X1 means the specific amino acid W or (ii) X1 means any amino acid residue excepted W, (i) X2 means the specific amino acid S or (ii) X2 means any amino acid residue excepted S, (i) X3 means the specific amino acid N or (ii) X3 means any amino acid residue excepted N, (i) X4 means the specific amino acid S or (ii) X4 means any amino acid residue excepted S, with the proviso that three out of the four amino acid residues X1, X2, X3 and X4 mean the specific amino acid defined in their respective meaning (i) above, and the remaining amino acid residue among X1 to X4 means any amino acid residue excepted the specific amino acid residue defined in its meaning (i), for preventing and/or treating an infection of an individual with an HIV-1 virus.

Compositions for preventing and/or treating an infection by an HIV-1 virus

The present invention relates to an immunogenic composition comprising an antigenic peptide of formula (I) below: Nt-S-X1-X2-X3-K-X4-Ct (I) [SEQ ID No 1], wherein &#x2014;Nt consists of a peptide having from 0 to 50 amino acids in length, &#x2014;Ct consists of a peptide having from 0 to 50 amino acids in length, &#x2014;each of X1 to X4 consists of an amino acid residue, wherein: &#x2014;(i) X1 means the specific amino acid W or (ii) X1 means any amino acid residue excepted W, &#x2014;(i) X2 means the specific amino acid S or (ii) X2 means any amino acid residue excepted S, &#x2014;(i) X3 means the specific amino acid N or (ii) X3 means any amino acid residue excepted N, &#x2014;(i) X4 means the specific amino acid S or (ii) X4 means any amino acid residue excepted S, with the proviso that &#x2014;three out of the four amino acid residues X1, X2, X3 and X4 mean the specific amino acid defined in their respective meaning (i) above, and &#x2014;the remaining amino acid residue among X1 to X4 means any amino acid residue excepted the specific amino acid residue defined in its meaning (i), for preventing and/or treating an infection of an individual with an HIV-1 virus.

The present invention relates to an immunogenic composition comprising an antigenic peptide of formula (I) below: Nt-S-X1-X2-X3-K-X4-Ct (I) [SEQ ID No 1], wherein&#x2014;Nt consists of a peptide having from 0 to 50 amino acids in length, &#x2014;Ct consists of a peptide having from 0 to 50 amino acids in length, &#x2014;each of X1 to X4 consists of an amino acid residue, wherein: &#x2014;(i) X1 means the specific amino acid W or (ii) X1 means any amino acid residue excepted W, &#x2014;(i) X2 means the specific amino acid S or (ii) X2 means any amino acid residue excepted S, &#x2014;(i) X3 means the specific amino acid N or (ii) X3 means any amino acid residue excepted N, &#x2014;(i) X4 means the specific amino acid S or (ii) X4 means any amino acid residue excepted S, with the proviso that&#x2014;three out of the four amino acid residues X1, X2, X3 and X4 mean the specific amino acid defined in their respective meaning (i) above, and&#x2014;the remaining amino acid residue among X1 to X4 means any amino acid residue excepted the specific amino acid residue defined in its meaning (i), for preventing and/or treating an infection of an individual with an HIV-1 virus.

Compositions for detecting an infection by an HIV-1 virus

The present invention relates to the field of the in vitro diagnosis of the progression status of an infection of an individual with a virus belonging to the family of the Human Immunodeficiency Viruses (HIV) as well as with the therapeutical treatment of this infectious disease.

Purified antibody to the extracellular domain of NKp44L

The present invention provides a method for the design and/or the selection of agonist or antagonist chemokine variants combining a phage display technology and a screening on living cells expressing the receptor of the corresponding native chemokine. It also provides RANTES variants having agonist properties towards said receptor, and methods for preventing and/or curing viral diseases, as well as clues for preventing and/or curing inflammatory or malignant diseases.

Methods for construction and screening of libraries of chemokine variants

Methods and construction and screening of libraries of chemokine variants

Maturation of hemopoietic cells

The invention concerns a pharmaceutical preparation comprising the 25K IgE-binding factor (25K IgE-bf) and interleukin-1 (IL-1), and the use of said pharmaceutical preparation for the stimulation of the maturation of prothymocytes, e.g. for the treatment of T cell immunodeficiencies and prothymocyte leukemias.

Pharmaceutical preparation for the maturation of prothymocytes

Growing community of inventors

Paris, France

Patrice Debre